Tata Institute in Mumbai, India, has unveiled a groundbreaking tablet designed to prevent cancer recurrence. After a decade of dedicated research, the institute’s team of researchers has developed a cutting-edge therapy targeting the release of chromatin particles from dying cancer cells. These particles can potentially transform healthy cells into cancerous ones.
The tablet, containing pro-oxidant compounds like resveratrol and copper (R+Cu), works by generating oxygen radicals. These radicals neutralize chromatin particles, halting the spread of cancerous cells throughout the body. This innovative treatment aims not only to reduce the side effects associated with traditional therapies, such as radiation and chemotherapy, by up to 50%, but also to prevent cancer recurrence.
Also Read : Takeda’s Dengue Vaccine Qdenga: A New Hope for India’s Fight Against Dengue Fever
Termed the “Magic of R+Cu,” this therapy represents a significant advancement in cancer care. However, before it can be widely distributed, the tablet must undergo rigorous evaluation and approval from regulatory authorities, including the Food Safety and Standards Authority of India (FSSAI). Once approved, it is anticipated to be available in the market by June-July, offering hope and relief to countless cancer patients.
Priced affordably at just ₹100, this solution has the potential to democratize cancer treatment, making it accessible to a broader population. Human trials are currently underway to further assess the tablet’s efficacy and safety. Early results show promising reductions in treatment-related side effects.
Overall, this achievement signifies a triumph in medical innovation, reflecting Tata Institute’s dedication to advancing cancer treatment and improving patient outcomes.
